Multimodal neurometabolic investigation of the effects of zolpidem on leukoencephalopathy-related apathy

C. Delorme, I. Adanyeguh, D. Bendetowicz, I. Le Ber, A. Ponchel, A. Kas, M-O Habert, F. Mochel

► To cite this version:

C. Delorme, I. Adanyeguh, D. Bendetowicz, I. Le Ber, A. Ponchel, et al.. Multimodal neurometabolic investigation of the effects of zolpidem on leukoencephalopathy-related apathy. *European Journal of Neurology*, In press, 27 (11), pp.2297-2302. 10.1111/ene.14465 . hal-02948899

HAL Id: hal-02948899

<https://hal.sorbonne-universite.fr/hal-02948899>

Submitted on 25 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A **B**

A **B**

Multimodal neurometabolic investigation of the effects of Zolpidem on leukoencephalopathy-related apathy

Cécile Delorme¹, MD, Isaac Adanyeguh^{2,3}, PhD, David Bendetowicz^{1,2}, MD, Isabelle Le Ber^{2,4,5}, MD, PhD, Amélie Ponchel^{1,2}, PhD, Aurélie Kas^{6,7}, MD, PhD, Marie-Odile Habert^{6,7}, MD, PhD, Fanny Mochel^{2,8}, MD, PhD

- 1- AP-HP, Hôpital Pitié-Salpêtrière, Department of Neurology, F-75013, Paris, France
- 2- INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013, Paris, France.
- 3- Center for Magnetic Resonance Research (CMRR), University of Minnesota, Minneapolis, MN, United States.
- 4- Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP – Hôpital Pitié-Salpêtrière, 75013, Paris, France
- 5- Institut du Cerveau et de la Moelle Epinière (ICM), Frontlab, F-75013, Paris, France
- 6- Sorbonne Université, CNRS, INSERM, Laboratoire d’Imagerie Biomédicale, LIB, F-75006, Paris, France
- 7- AP-HP, Hôpital Pitié-Salpêtrière, Médecine Nucléaire, F-75013, Paris, France
- 8- AP-HP, Pitié-Salpêtrière University Hospital, Department of Genetics, F-75013, Paris, France.

Running title: Zolpidem in leukodystrophy-related apathy

Corresponding author :

Dr Fanny MOCHEL

Département de Génétique

Centre de Référence des Leucodystrophies et Leucoencéphalopathies rares

Hôpital La Pitié-Salpêtrière

47 Boulevard de l’Hôpital - 75013 - Paris – France

fanny.mochel@upmc.fr

Count:

Title: 94 characters, Running title: 43 characters

Abstract: 198 words; Text: 1554 words; Figures: 2; Supplementary material: 1 video.

Key words: Apathy, Zolpidem, Leukoencephalopathy, FDG-PET, GABA.

Data availability: All data concerning the study is available upon request to the corresponding author.

Conflict of interest disclosure: The authors have no competing interests.

Funding: None

Abstract

Background: The symptomatic effect of Zolpidem on apathy has been reported in neurological disorders such as strokes and post-anoxic brain injuries, but not in white matter disease of the brain.

Methods: We studied a 38-year-old patient presenting with severe apathy related to a genetic leukoencephalopathy but marked improvement of apathy after taking 10 milligrams of Zolpidem. To understand what may mediate such a clinical effect, we undertook a multimodal neurometabolic approach using ^{18}F Fluorodeoxyglucose (FDG)-PET metabolism and a dedicated magnetic resonance spectroscopy (MRS) sequence for GABA and glutamine/glutamate metabolism.

Results: Pre-Zolpidem FDG-PET showed hypometabolism in the orbitofrontal cortex, dorsolateral cortex and basal ganglia compared to healthy controls. Post-Zolpidem, FDG-PET displayed increased metabolism in the orbitofrontal cortex together with improvement in the emotional and auto-activation domains of apathy. There was no improvement in the cognitive domain of apathy, and no change in metabolism in the dorsolateral frontal cortex. Post-Zolpidem, MRS showed increased GABA and glutamine+glutamate levels in the frontal cortex and pallidum.

Conclusion: Our multimodal neurometabolic study suggests that the effects of Zolpidem on apathy are related to increased metabolism in the orbitofrontal cortex and basal ganglia secondary to GABA modulation. Zolpidem may improve apathy in other white-matter disorders.

Abbreviations

FDG: ^{18}F Fluorodeoxyglucose; MRS: magnetic resonance spectroscopy; ALSP: axonal spheroids and pigmented glia; Glx: glutamine+glutamate; tCr: total creatine.

Introduction

Apathy is defined as a quantitative reduction of goal-directed activity (1–3). Each dimension of apathy, namely cognitive, affective-emotional and auto-activation/self-initiating impairment seems to be related to distinct lesions of the prefrontal cortex and basal ganglia: respectively, dorsolateral, ventral (orbitofrontal/inferior) and medial prefrontal cortex regions as well as their corresponding projections to the basal ganglia (1). Apathy should rather be seen as a “network-related” cerebral dysfunction, involving white matter or multifocal lesions, than a focal disorder (4–7).

Zolpidem, a GABAergic non-benzodiazepine hypnotic, was found to enhance arousal and neuropsychiatric functions in some patients with stroke (8) or post-anoxic brain injuries, (9,10). Zolpidem can also alleviate catatonic syndromes (11–15). Zolpidem effects have never investigated in white matter disorders.

Here, we studied a patient with a genetic white matter disease characterized by severe apathy, who experienced marked improvement after Zolpidem. We undertook a multimodal approach using ^{18}F Fluorodeoxyglucose (FDG)-PET metabolism and a dedicated magnetic resonance spectroscopy (MRS) sequence for GABA and glutamine/glutamate metabolism, pre and post-Zolpidem, to understand what may mediate this effect.

Methods

Patient description and pharmacological intervention

The patient was 33 when she developed attentional difficulties and apathy. Her condition rapidly worsened with marked walking impairment, severe cognitive disturbances and spasticity. Brain MRI showed patchy asymmetric white matter hyperintensities on fluid-attenuated inversion recovery sequence, and lesions with increased diffusivity on diffusion weighted imaging sequence (data not shown). She was diagnosed with multiple sclerosis, but diagnosis was reconsidered due to the very atypical and rapid evolution. Axonal spheroids and pigmented glia (ALSP) was suspected and confirmed by *CSF1R* gene sequencing, which identified a heterozygous c.2342C>T (p.A781V) pathogenic variant (16). At age 38, she could only walk a few steps with help due to frontal disturbances. She had marked pyramidal syndrome but no muscle deficit. She had dementia with evidence of frontal dysfunction.

The patient was enrolled in a study on frontotemporal lobar degeneration approved by Inserm ethical committee (Inserm RBM 02-059). FDG-PET and MRS were performed before (after a wash-out of more than 12 hours) and one hour after taking orally 10 milligrams of Zolpidem. FDG-PET was used for the therapeutic evaluation of Zolpidem, with a low total radiation dose (4.6 mSv), and data use was approved by the French authority for the protection of privacy and personal data in clinical research (CNIL, approval No. 2111722). Written informed consent was obtained from the patient and her caregiver for clinical investigation including repeat FDG-PET and MRS, video and publication.

FDG-PET

A 10 minutes acquisition was performed with a hybrid PET/CT system (Biograph mCT Flow - Siemens Healthcare) 30 min after the intravenous injection of FDG (2 MBq/Kg). PET volumes were co-registered, spatially normalized in the Montreal Neurological Institute (MNI) space using SPM12 (<https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>), smoothed and normalized in intensity. Two-sample T-tests were used to compare the patient's metabolism to normal controls, with a general linear model with age and gender as covariates. The primary cluster-defining threshold was $p=0.001$, with the cluster-level extent threshold set at $p = 0.05$ for false discovery rate correction.

A z-score mapping implemented in BrainVisa software (<http://brainvisa.info>) was used to extract areas with differences in metabolism before and after Zolpidem. Relative difference was computed into z-scores as described (17,18). Clusters < 100 voxels (8ml) and voxels with absolute values < 1.5 z-score were excluded before displaying z-score maps onto anatomical MRI.

Magnetic Resonance Spectroscopy

MRS was performed on a 3-Tesla Siemens Prisma fit scanner (Siemens Medical Solutions, Erlangen, Germany). Single volume MEGA-Point-Resolved Spectroscopy (MEGA-PRESS, TR = 2000 ms, TE = 68 ms, averages = 48) was used to acquire data in a 17 x 35 x 15 mm³ and 15 x 20 x 20 mm³ volumes of interest in the medial frontal cortex and pallidum respectively. Consecutive application of spectral editing pulses at 1.9 ppm (MEGA-ON) and 7.5 ppm (MEGA-OFF) was performed for enhanced detection of low-concentrated metabolites including GABA and Glx (glutamine + glutamate). The difference of the ON and OFF spectra revealed the GABA and Glx signals that usually overlap with higher concentrated metabolites. Quantification of the spectra was done using LCModel (19). The ratio of GABA/total creatine (tCr) and Glx/tCr were reported.

Results

Clinical evaluation

Behavioral examination before Zolpidem revealed major apathy involving all three dimensions, with executive dysfunction, affective indifference, emotional flattening, anhedonia, and lack of initiative to undertake spontaneous actions or elaborate about future projects (Supplementary Video, Part 1). Cognitive examination was limited due to severe distractibility and slowing of thoughts. She scored 17/30 on the Mimi Mental State Examination, 2/18 on the Frontal Assessment Battery and 10/30 on the Montreal Cognitive Assessment.

One hour after taking 10 mg of Zolpidem, the patient was more alert, responsive and able to communicate more fluently (Supplementary Video, Part 2). There was a marked increase in the emotional and social content of her conversation. She did elaborate on some future projects such as doing an around the world travel with her family. Neuropsychological scores otherwise remained unchanged and a severe executive deficit persisted. Patient's participation to clinical examination clearly improved, including her ability to walk. There was also a marked increase in spontaneous motor expression, with increased and more rapid facial and bodily movements. The effect of Zolpidem was reproductive over days and lasted for about four hours.

FDG-PET

Pre-Zolpidem cerebral FDG-PET showed hypometabolism in the bilateral cerebellum, the pons, orbitofrontal cortex, thalamus, cingulate, and dorsolateral prefrontal cortex compared to a cohort of healthy controls (Figure 1A).

Post-Zolpidem cerebral FDG-PET showed increased metabolism in the orbitofrontal cortex, the median prefrontal cortex, the caudate nucleus and the thalamus compared to pre-Zolpidem acquisitions (Figure 2). Post- Zolpidem metabolism in the orbitofrontal cortex was not significantly decreased compared to healthy controls (Figure 1B).

Magnetic resonance spectroscopy

Post-Zolpidem, we observed increased ratios of GABA/tCr and Glx/tCr in the medial frontal cortex and pallidum compared to pre-Zolpidem (Figure 2B).

Discussion

We report the marked clinical response to Zolpidem of a patient with severe apathy in the context of a white-matter disease. Our multimodal neurometabolic study revealed that Zolpidem increased metabolism in the orbitofrontal cortex and basal ganglia, and increased GABA and Glx levels in the medial prefrontal cortex and pallidum.

ALSP is one of the most common leukodystrophies and is a model of microglia dysfunction (20). Neuropsychiatric manifestations of ALSP include cognitive decline, apathy, and other behavioral changes resembling behavioral-variant frontotemporal dementia (16). ALSP predominantly affects the white matter, in particular the frontal subcortical white matter and corpus callosum (20,21). FDG-PET in ALSP patients showed diffuse hypometabolism predominantly affecting the frontal and parietal lobes (21,22).

Pre-Zolpidem FDG-PET in our patient displayed significant hypometabolism in brain regions involved in motivation and goal-directed behaviors, namely the orbitofrontal cortex, medial prefrontal cortex and basal ganglia. Post-Zolpidem FDG-PET showed increased metabolism in these regions. These results are consistent with the three-dimensional model of apathy (1) as, post-Zolpidem, our patient showed emotional-affective and auto-activation improvement contrasting with persisting severe executive disturbance. This response was paralleled by increased FDG-PET metabolism in the orbitofrontal cortex, median prefrontal cortex and basal ganglia but no change in the dorsolateral frontal regions. It has been hypothesized that, in some leukodystrophies, frontal neuropsychiatric symptoms might reflect a “disconnection syndrome” secondary to white matter alterations rather than a cortical dysfunction (23,24). Apathy is frequent in other white matter diseases, such as small vessel diseases (25) and multiple sclerosis (26).

Zolpidem increased GABA and Glx in our two MRS regions of interest, the medial frontal cortex and the pallidum. In healthy controls, decreased GABA/Cr ratio in response to Zolpidem has been reported previously in the thalamus but with no effect on Glx (27). The binding of Zolpidem in healthy controls, in which the glutamatergic/GABAergic balance is not impaired, leads to cortical inhibition. Conversely, increased GABA/Cr ratio has been reported in the thalamus and anterior cingulate of patients with major depressive disorder after Zolpidem administration (28). Hence, the effect of Zolpidem seems to be influenced by changes in receptor configurations and how the glutamatergic / GABAergic balance is affected by neuropsychiatric disorders.

Zolpidem can improve cognitive function in some patients with post-hypoxic brain injuries, which also affect the white matter (29). One common hypothesis is that the cortical disconnection related to white matter alterations induces allosteric changes in GABA receptors, which may become hypersensitive in order to keep their function even with low GABAergic tone. In line with this

hypothesis, a ^{18}F Flumazenil PET study showed increased GABA receptors activity in the frontoparietal regions in a patient with hypoxic brain injury (30). Zolpidem may enhance cortical function by reversing this functional diaschisis, as suggested by our MRS findings. Zolpidem is specific for GABA_A-receptors containing the $\alpha 1$ subunit, which are predominantly expressed in the thalamus and the striatum (31–34). Zolpidem binding may inhibit the internal pallidum, which would in turn disinhibit thalamus and activate thalamo-cortical projections and result in a “deep brain stimulation-like” effect (35,36).

This study has several limitations. It was not placebo-controlled and was performed on a single subject. The severe frontal cognitive impairment made it difficult to provide a more detailed clinical examination, for example social cognition evaluations that require a preserved working memory and attention. Although we cannot draw definite conclusions about the mode of action of Zolpidem on apathy, our multimodal approach suggests that its effects are related to increased metabolism in the orbitofrontal cortex and basal ganglia secondary to GABA modulation.

References

1. Levy R, Dubois B. Apathy and the Functional Anatomy of the Prefrontal Cortex–Basal Ganglia Circuits. *Cerebral Cortex*. 1 juill 2006;16(7):916-28.
2. Marin RS. Apathy: a neuropsychiatric syndrome. *J Neuropsychiatry Clin Neurosci*. 1991;3(3):243-54.
3. Robert P, Lanctôt KL, Agüera-Ortiz L, Aalten P, Bremond F, Defrancesco M, et al. Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group. *European Psychiatry*. 1 oct 2018;54:71-6.
4. Hahn C, Lim H-K, Won WY, Ahn KJ, Jung W-S, Lee CU. Apathy and White Matter Integrity in Alzheimer's Disease: A Whole Brain Analysis with Tract-Based Spatial Statistics. Herholz K, éditeur. *PLoS ONE*. 3 janv 2013;8(1):e53493.
5. Yang S, Hua P, Shang X, Cui Z, Zhong S, Gong G, et al. Deficiency of brain structural sub-network underlying post-ischaemic stroke apathy. *Eur J Neurol*. févr 2015;22(2):341-7.
6. Le Heron C, Apps MAJ, Husain M. The anatomy of apathy: A neurocognitive framework for amotivated behaviour. *Neuropsychologia*. sept 2018;118:54-67.
7. Sheelakumari R, Bineesh C, Varghese T, Kesavadas C, Verghese J, Mathuranath PS. Neuroanatomical correlates of apathy and disinhibition in behavioural variant frontotemporal dementia. *Brain Imaging and Behavior* [Internet]. 4 juill 2019 [cité 23 juill 2019]; Disponible sur: <http://link.springer.com/10.1007/s11682-019-00150-3>
8. Autret K, Arnould A, Mathieu S, Azouvi P. Transient improvement of poststroke apathy with zolpidem: a single-case, placebo-controlled double-blind study. *Case Reports*. 8 févr 2013;2013(feb08 1):bcr2012007816-bcr2012007816.
9. Cohen L, Chaaban B, Habert M-O. Transient improvement of aphasia with zolpidem. *N Engl J Med*. 26 févr 2004;350(9):949-50.
10. Bomalaski MN, Claflin ES, Townsend W, Peterson MD. Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. *JAMA Neurology*. 1 sept 2017;74(9):1130.
11. Mastain B, Vaiva G, Guerouaou D, Pommery J, Thomas P. Effet favorable du zolpidem sur un état catatonique. *Rev Neurol (Paris)*. janv 1995;151(1):52-6.
12. Thomas P, Rasle C, Mastain B, Maron M, Vaiva G. Test for catatonia with zolpidem. *The Lancet*. 1997;349(9053):702.
13. Zaw ZF, Bates GDL. Replication of zolpidem test for catatonia in an adolescent. *The Lancet*. 1997;349(9069):1914.
14. Thomas P, Cottencin O, Rasle C, Vaiva G, Goudemand M, Bieder J. Catatonia in French Psychiatry: Implications of the Zolpidem Challenge Test. *Psychiatr Ann*. 1 janv 2007;37(1).
15. Javelot H, Michel B, Steiner R, Javelot T, Cottencin O. Zolpidem test and catatonia. *J Clin Pharm Ther*. déc 2015;40(6):699-701.
16. Konno T, Yoshida K, Mizuno T, Kawarai T, Tada M, Nozaki H, et al. Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with *CSF1R* mutation. *European Journal of Neurology*. janv 2017;24(1):37-45.
17. Huberfeld G, Habert M-O, Clemenceau S, Maksud P, Baulac M, Adam C. Ictal brain hyperperfusion contralateral to seizure onset: the SPECT mirror image. *Epilepsia*. janv 2006;47(1):123-33.
18. Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P, et al. Motor cortex and hippocampus are the two main cortical targets in LGII-antibody encephalitis. *Brain*. avr 2016;139(Pt 4):1079-93.
19. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magn Reson Med*. déc 1993;30(6):672-9.
20. Konno T, Kasanuki K, Ikeuchi T, Dickson DW, Wszolek ZK. *CSF1R* -related leukoencephalopathy: A major player in primary microgliopathies. *Neurology*. 11 déc 2018;91(24):1092-104.
21. Freeman SH, Hyman BT, Sims KB, Hedley-Whyte ET, Vossough A, Frosch MP, et al. Adult

Onset Leukodystrophy with Neuroaxonal Spheroids: Clinical, Neuroimaging and Neuropathologic Observations. *Brain Pathology*. janv 2009;19(1):39-47.

22. Ueda S, Yamashita H, Hikami R, Sawamoto N, Yoshida K, Takahashi R. A novel A792D mutation in the CSF1R gene causes hereditary diffuse leukoencephalopathy with axonal spheroids characterized by slow progression. *eNeurologicalSci*. mars 2015;1(1):7-9.

23. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric Disturbances in Metachromatic Leukodystrophy: Insights Into the Neurobiology of Psychosis. *Arch Neurol*. 1 avr 1992;49(4):401-6.

24. Baumann N, Turpin J-C, Lefevre M, Colsch B. Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationships? *Journal of Physiology-Paris*. mai 2002;96(3-4):301-6.

25. Reyes S, Viswanathan A, Godin O, Dufouil C, Benisty S, Hernandez K, et al. Apathy: A major symptom in CADASIL. *Neurology*. 10 mars 2009;72(10):905-10.

26. Rosti-Otajärvi E, Hämäläinen P. Behavioural symptoms and impairments in multiple sclerosis: a systematic review and meta-analysis. *Mult Scler*. janv 2013;19(1):31-45.

27. Licata SC, Jensen JE, Penetar DM, Prescott AP, Lukas SE, Renshaw PF. A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4 T. *Psychopharmacology*. mai 2009;203(4):819-29.

28. Licata SC, Jensen JE, Conn NA, Winer JP, Lukas SE. Zolpidem increases GABA in depressed volunteers maintained on SSRIs. *Psychiatry Research: Neuroimaging*. oct 2014;224(1):28-33.

29. Whyte J, Myers R. Incidence of Clinically Significant Responses to Zolpidem Among Patients with Disorders of Consciousness: A Preliminary Placebo Controlled Trial. *American Journal of Physical Medicine & Rehabilitation*. mai 2009;88(5):410-8.

30. Kim C, Kwon BS, Nam KY, Park JW, Lee HJ. Zolpidem-Induced Arousal by Paradoxical GABAergic Stimulation: A Case Report With F-18 Flumazenil Positron Emission Tomography and Single Photon Emission Computed Tomography Study. *Annals of Rehabilitation Medicine*. 2016;40(1):177.

31. Churchill L, Bourdelais A, Austin MC, Lolait SJ, Mahan LC, O'Carroll A-M, et al. GABAA receptors containing alpha1 and alpha2 subunits are mainly localized on neurons in the ventral pallidum. *Synapse*. juin 1991;8(2):75-85.

32. Chen L, Savio Chan C, Yung W-H. Electrophysiological and behavioral effects of zolpidem in rat globus pallidus. *Exp Neurol*. avr 2004;186(2):212-20.

33. Mortensen M, Patel B, Smart TG. GABA Potency at GABAA Receptors Found in Synaptic and Extrasynaptic Zones. *Front Cell Neurosci* [Internet]. 20 janv 2012 [cité 11 août 2019];6. Disponible sur: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262152/>

34. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The Distribution of 13 GABA_A Receptor Subunit mRNAs in the Rat Brain. I. Telencephalon, Diencephalon, Mesencephalon. :23.

35. Schiff ND. Mesocircuit Mechanisms Underlying Recovery of Consciousness Following Severe Brain Injuries: Model and Predictions. In: Monti MM, Sannita WG, éditeurs. *Brain Function and Responsiveness in Disorders of Consciousness* [Internet]. Cham: Springer International Publishing; 2016 [cité 1 juill 2018]. p. 195-204. Disponible sur: http://link.springer.com/10.1007/978-3-319-21425-2_15

36. Badillo SPJ, Jamora RDG. Zolpidem for the Treatment of Dystonia. *Front Neurol*. 17 juill 2019;10:779.

Figure Legends

Figure 1 - Pre- and post-Zolpidem FDG-PET

In blue are shown regions with significant hypometabolism in the patient compared to a cohort of healthy controls ($p < 0.05$ after cluster correction). A- Pre-Zolpidem. B- Post-Zolpidem.

Figure 2 – Post-Zolpidem neurometabolic response

A. FDG-PET. In red are shown regions with significant post-Zolpidem increased metabolism compared to the pre-Zolpidem acquisition. B. MR-Spectroscopy. GABA/Cr and Glx/Cr ratios in the medial frontal and pallidum before and after 10 mg of Zolpidem. Metabolite concentrations are in $\mu\text{mol/g}$. *Cr*: total creatine; *Glx*: glutamine+ glutamate.

Video legend

Part 1 – Before Zolpidem

Part 2 – One hour after 10 mg of Zolpidem.